Patent · US Active

Anti-PDL1, IL-15 and TGF-beta receptor combination molecules

US11168138B2 · kind B2 · utility

14Cited by
4References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 26, 2019
Grant dateNov 9, 2021
Priority date
Expiry dateJul 4, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/74
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant, a cytokine receptor or cytokine ligand, and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.